Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Shareholder Meeting (November 2019)
19 slides from Proteomics International Laboratories's shareholder meeting presentation, Nov 28, 2019
Slide 1: AGM Presentation – Building a Global Diagnostics Business
For personal use only AGM Presentation 28th November 2019 BUILDING A GLOBAL ASX: PIQ DIAGNOSTICS BUSINESS
Slide 2: Disclaimer
DISCLAIMER For personal use only This Presentation is provided by Proteomics International Laboratories Ltd (PILL, the Company). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to se
Slide 3: Corporate Overview
CORPORATE OVERVIEW For personal use only Proteomics International Laboratories Ltd (ASX: PIQ) is a medical CORPORATE SNAPSHOT* – 27/11/2019 ASX code PIQ technology company at the forefront of predictive diagnostics Share Price $0.315 and bioanalytical services Shares on issue 92m PREDICTIVE DIAGNOST
Slide 4: Building a Global Diagnostics Business
BUILDING A GLOBAL DIAGNOSTICS BUSINESS For personal use only PromarkerD, a predictive test for diabetic kidney disease (DKD) is being rolled out now. 425m ENORMOUS MARKET adults have diabetes globally – 1 in 3 currently have DKD. DE-RISKED CLINICALLY PromarkerD clinical studies completed and validat
Slide 5: Proteomics vs Typical Biotechs
PROTEOMICS Vs TYPICAL BIOTECHS For personal use only ALL THE UPSIDE WITHOUT THE CLINICAL RISKS, COSTS & EXTENDED TIMELINES Features PIQ Typical Biotechs Enormous markets ✓ ✓ Minimal clinical risk ✓ X No waiting for results ✓ X Short clinical development (for new products) ✓ X No binary outcome ✓ X L
Slide 6: Promarker – Platform Technology
PROMARKER – PLATFORM TECHNOLOGY For personal use only PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics to formulate commercial diagnostic tests 6
Slide 7: The Promarker Technology
THE PROMARKER TECHNOLOGY For personal use only PLATFORM TECHNOLOGY : PROMARKERTM PromarkerD – DIABETIC KIDNEY DISEASE TEST ANALYTICAL SERVICES ▪ PromarkerD – predictive test for diabetic kidney ▪ State-of-the-art biomarker analysis facility disease up to four years in advance ▪ Best in class Quality
Slide 8: PromarkerD: Predictive Test for Diabetic Kidney Disease
PromarkerD For personal use only PREDICTIVE TEST FOR DIABETIC KIDNEY DISEASE 8
Slide 9: Market Size? Undiagnosed
50% Nth America & Caribbean MARKET SIZE? UNDIAGNOSED Africa Europe For personal use only South & Central America South-East Asia ➢ Hundreds of millions of Middle East & North Africa people could benefit from Western Pacific this test in terms of early Africa treatment to mitigate the Sth/Ctrl Americ
Slide 10: A Major Opportunity
A MAJOR OPPORTUNITY For personal use only THE PROBLEM 425 million people have diabetes 1 in 3 diabetic adults currently develop chronic kidney disease There are no early symptoms of diabetic kidney disease. Kidney function can fall below 15-20% with no symptoms. There is currently no available test
Slide 11: Major Cost/Benefit Factor to Drive Uptake
MAJOR COST/BENEFIT FACTOR TO DRIVE UPTAKE For personal use only With PromarkerD Without PromarkerD Unequivocal Cost Benefit Test Price US$55 Dialysis cost US$72,000 per year Predicts kidney disease with 86% VS ongoing for the patient’s life accuracy up to four years out Unequivocal Patient Benefit N
Slide 12: Tests Built to Capture Mass Market
TESTS BUILT TO CAPTURE MASS MARKET For personal use only LABORATORY DEVELOPED TEST (LDT) IN VITRO DIAGNOSTIC TEST (IVD) ▪ Utilises mass spectrometry or immunoassay ▪ Utilises the immunoassay with key antibody technology to identify specific biomarker proteins reagents to identify specific biomarker
Slide 13: Market Breakdown – PromarkerD
MARKET BREAKDOWN - PromarkerD For personal use only MARKET SIZE TOTAL POTENTIAL REGION PARTNER (DIABETICS) OPPORTUNITY* Spain Patia Europe 3.6m US$20m p.a. Mexico Patia Biopharma 13m US$72m p.a. Dominican Republic Omics Global 1.1m US$6m p.a. TARGET MARKETS United States In Discussions 30m US$165m p
Slide 14: Janssen Collaboration
JANSSEN COLLABORATION For personal use only Proteomics and Janssen Research & Development (Janssen) have formed a collaboration, utilising PromarkerD to help assess the effectiveness of canagliflozin (Janssen diabetes drug) as a treatment for diabetic kidney disease. POSITIVE PHASE 3 RESULTS POTENTI
Slide 15: Further Global Potential in New Markets
FURTHER GLOBAL POTENTIAL IN NEW MARKETS For personal use only Proteomics endeavours to leverage its PromarkerTM Platform DIAGNOSTICS to develop and commercialise a suite of diagnostic tests Potential for faster market adoption for a new diagnostic test, PIPELINE post a successful PromarkerD commerci
Slide 16: Analytical Services
ANALYTICAL SERVICES For personal use only WORLD’S FIRST COMPANY TO RECEIVE ISO 17025 LABORATORY ACCREDITATION FOR PROTEOMICS SERVICES (PROTEIN TESTING) BIOSIMILARS & BIOLOGICS PHARMACOKINETIC TESTING Assisting pharmaceutical companies Pre-clinical and clinical quantitative develop generic drugs test
Slide 17: Milestones & Upcoming Catalysts
MILESTONES & UPCOMING CATALYSTS For personal use only EXCEPTIONAL GLOBAL OPPORTUNITY SHARE PRICE CATALYSTS ✓ Proven diagnostics business with global potential PromarkerD ✓ Scalable licensing model with high margins and ➢ Further licencing deals in major territories negligible rollout cost - diagnost
Slide 18: Board & Management
BOARD & Terry Sweet FAICD, Chairman Director of several listed companies over the past 30 years in both executive and MANAGEMENT non-executive capacities. Companies include XRFAfrica Scientific Ltd, where he was For personal use only South & Managing Director for 4 years, Western Biotechnology Ltd,
Slide 19: Contact
CONTACT For personal use only Richard Lipscombe Dirk van Dissel Managing Director Corporate Advisor & Investor Relations T: +61 8 9389 1992 Adelaide Equity Partners E: r.lipscombe@proteomicsinternational.com T: +61 8 8232 8800 www.proteomicsinternational.com E: dvandissel@adelaideequity.com.au Alast
Proteomics International Laboratories — Shareholder Meeting (November 2019) on 6ix